Comparison of the Efficacy and Tolerability of T1210 and Olopatadine Hydrochloride 0.1% in the Treatment of Seasonal Allergic Conjunctivitis

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01344083

Enrollment

Registered

2011-04-28

Start date

2011-04-30

Completion date

2012-02-29

Last updated

2012-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seasonal Allergic Conjunctivitis

Brief summary

The aim of this study is to compare the efficacy and the safety of T1210 versus Olopatadine eye drops in the topical treatment of seasonal allergic conjunctivitis.

Interventions

DRUGT1210

2 drops T1210 once a day

DRUGOlopatadine hydrochloride

2 drops once a day Olopatadine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Written informed consent * Conjunctivitis allergic conjunctivitis

Exclusion criteria

* Severe ocular allergy * Vernal keratoconjunctivitis

Design outcomes

Primary

Measure	Time frame
Change from baseline of the score of tearing	Day 28
Change from baseline of the score of itching	Day 28
Change from baseline of the score of conjunctival hyperaemia	Day 28

Secondary

Measure	Time frame
Global local tolerance assessment by the Investigator and the patient	Day 7

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026